Navigation Links
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies
Date:11/20/2008

SAN MARINO, Calif., Nov. 20 /PRNewswire/ -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months. Analysis of safety and efficacy data showed no major toxicity, while documenting significant control of tumor growth.

Analysis of efficacy in 42 patients with bone and soft tissue sarcoma showed a dose-response relationship between overall survival and Rexin-G which was highly significant. A confirmatory Phase II study in 17 osteosarcoma patients showed a median overall survival greater than seven months; that is, after failing standard chemotherapies. Two patients are disease-free greater than 6 months after surgical resection of residual tumors and Rexin-G given as both neoadjuvant and adjuvant monotherapy. These studies indicate that (i) intravenous Rexin-G is safe and well-tolerated, and (ii) Rexin-G controls tumor growth and improves survival in a dose-dependent manner in patients with chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about Rexin-G and Epeius Biotechnologies' pipeline of proprietary compounds currently available for clinical development, please visit us at http://www.epeiusbiotech.com .

*(LOGO 72dpi: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

This release was issued on behalf of the above
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
2. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
3. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
4. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
5. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
6. New Insight Into the Controls on a Go-To Enzyme
7. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
8. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
9. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013 Royal Philips (NYSE: PHG, ... Performance Leader in Imaging Equipment in the 2013 Best ... also received Best in KLAS and Best in Category ... 128 Computed Tomography (CT), Ingenia 1.5T and 3.0T ... The annual Best in KLAS Awards: Medical Imaging & ...
(Date:6/18/2013)... June 18, 2013  Specialty Coating Systems ... in Parylene coating technologies: SCS microRESIST™ Antimicrobial ... of Parylene with antimicrobial properties to effectively ... components. (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ... increase and continue to pose a challenge ...
(Date:6/18/2013)... -- Decision Resources, one of the world,s leading research and ... the past 12 months, 25 percent of surveyed physicians from ... , Italy , Spain ... have been required to change the antiretroviral (ARV) prescription for ... costs. Additionally, more than 40 percent of respondents report that ...
Breaking Medicine Technology:Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS 2Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 2One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 3
... Nov. 7, 2011 Zimmer Holdings, Inc. ... agreed to sell $550 million of senior notes in an ... Smith Incorporated, BNP Paribas Securities Corp. and RBS Securities ... LLC, Credit Suisse Securities (USA) LLC, Citigroup Global Markets ...
... 7, 2011 ERT (Nasdaq: ERT ), ... President and CEO is scheduled to present at the ... on Nov. 15, 2011 in Las Vegas. ... Company,s corporate website at http://www.ert.com . The webcast ...
Cached Medicine Technology:Zimmer Holdings, Inc. Agrees to Sell $550 Million of Senior Notes 2ERT to Present at the Citi 2011 Global Health Care Conference on November 15, 2011 2
(Date:6/18/2013)... Medical Center clinical researchers have launched an innovative ... evaluate the ability of a patient,s own stem ... peripheral arterial disease (PAD). , Led by ... University Hospitals Case Medical Center,s Harrington Heart & ... Western Reserve University School of Medicine, the clinical ...
(Date:6/18/2013)... Belleville, Ill. (PRWEB) June 18, 2013 More ... older are living with HIV/AIDS, according to the Centers for ... don’t know they are infected. In support of National HIV ... Social Security Disability Insurance (SSDI) representation, the CDC ... HIV testing. , The CDC reports about 50,000 new ...
(Date:6/18/2013)... 2013 myCNAjobs announces the addition of ... articles, and tips to the Caregiver Resources Center. , ... the 10,000+ retiring baby boomers each day, the need ... job resources has never been greater. myCNAjobs, ... community, recently launched the first-ever free resource center for ...
(Date:6/18/2013)... 18, 2013 A new $119 million ... burgeoning aquaculture industry is redefining the way consumers get ... most acclaimed personal culinary chefs on the Emerald Coast ... of sustainable seafood and the promising industry of aquaculture. ... days. Many consumers strive to fully partake in the ...
(Date:6/18/2013)... Pomona, Calif. (PRWEB) June 18, 2013 ... associate professor of Family Medicine for the College of ... of Health Sciences has been elected president of the ... Gov. Edmund G. Brown Jr. appointed Connett, a 1984 ... , OMBC members recently elected Connett to the position ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:myCNAjobs Adds New Resources to Growing Caregiver Career Center 2Health News:New $119 Million Industry Swimming Up the East Coast 2
... likely to be infected with Hepatitis C virus compared ... get treatment for their liver disease because current antiviral ... this epidemiological background, the article by Schaefer and colleagues, ... important study in the field, write Sanjeev Arora and ...
... 72 posters, lectures, and mini-symposia given by University of Pennsylvania ... new research findings on the molecular workings of several types ... American Society of Cell Biology takes place on December 1-5, ... Huntington,s Disease: A new role has been discovered for ...
... 3 inVentiv Health, Inc.,(Nasdaq: VTIV ) today ... be held Tuesday, December 11th, 2007 in New York ... 9:00 a.m. as announced earlier, and,will conclude at noon, ... business overview, presentations by the,leaders of each of the ...
... N.C., Dec. 3 LipoScience, Inc. is pleased to,announce ... of Directors., Mr. Landon has over 30 years ... retiring from active management, Mr. Landon,was Vice President & ... full functional responsibility for all of DuPont,s Medical,Products businesses, ...
... research from a lab at Florida State University reveals ... it, resisting temptations to misbehave, our fuel tank is ... , Florida State psychologist Roy F. Baumeister and his ... M. Tice, Florida State, showed this with an experiment ...
... An inhaled immune system stimulant protects mice against ... and fungal infections of the lungs, a research ... Texas M. D. Anderson Cancer Center reports at ... have implications for protecting immuno-compromised patients against infection ...
Cached Medicine News:Health News:Treating patients with psychiatric disorders for hepatitis C 2Health News:Penn talks at ASCB touch on cancer, neurodegenerative diseases, and MD 2Health News:inVentiv Health Provides Updated Information on December 11th Investor Day 2Health News:inVentiv Health Provides Updated Information on December 11th Investor Day 3Health News:Got sugar? Glucose affects our ability to resist temptation 2Health News:Aerosol launches immune response in lungs to wipe out lethal infections 2Health News:Aerosol launches immune response in lungs to wipe out lethal infections 3
... ,Offers an average 5:1 increase in usage time ... of a standard cannula. , ,The combination ... ambulatory oxygen patients a superior alternative to liquid ... warranty. , ,NOTE: ...
Redesigning the World's Oxygen Therapy One Device at a Time. , ,Everything you like about our OXYMATIC 400 Series conservers, only better!...
... Accutrol is similar in design to the ... incorporates a temperature probe at the tip ... can accurately determine the patient's core body ... accuracy comparable to a pulmonary artery catheter ...
... Ultra Micro Shafts For Insertion Through A ... Light-Weight ... Shafts For A More Comfortable Approach., ,Recessed ... Cap Supplied For Protection Of Jaws During ...
Medicine Products: